NP Thyroid

Case Name (Date)

Faulkner et al. v. Acella Pharmaceuticals, LLC
22-cv-92, N.D. Ga.
(May 2022)

Product/Service

NP Thyroid

Allegations

Falsely marketing that medications contain a specific amount of the active ingredient when certain batches were recalled for containing too much or too little of the active ingredient

Falsely marketing medications as safe when certain batches were recalled because the amount of the active ingredient could cause serious adverse health consequences or death

Falsely marketing that medications are “[m]ade with the highest quality standards” and comply with applicable USP standards